Table 2 Clinical and pathological characteristics in HER2-positive early breast cancer according to TGFBI promoter methylation levels
From: Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
Characteristics | % N = 10 | p value* | |
|---|---|---|---|
n | Median (p25–p75) | ||
Age | 10 | −0.383* | 0.275*1 |
Menopause | 0.151*2 | ||
Premenopausal | 5 | 32.13 (24.58–35.86) | |
Postmenopausal | 5 | 14.58 (−0.68–25.77) | |
ER | 0.089*2 | ||
Negative | 2 | 2.85 (−3.57–9.28) | |
Positive | 8 | 28.50 (19.58–34.00) | |
HER2 status | – | ||
FISH | 0 | – | |
IHC+ | 10 | 25.18 (9.28–32.13) | |
Histological grade | – | ||
Grade 1–2 | 10 | 25.18 (9.28–32.13) | |
Grade 3 | 0 | – | |
Clinical stage | 0.804*3 | ||
IIB | 2 | 16.15 (−3.57–25.86) | |
IIIA | 2 | 19.58 (14.58–24.58) | |
IIIB | 6 | 28.50 (9.28–32.13) | |
Pathological response | – | ||
No response | 1 | 9.28 | |
Partial response | 9 | 25.77 (14.58–32.13) | |
Percentage of tumor shrinkage** | 10 | 0.029 | 0.957*1 |
Miller & Payne | 1.000*2 | ||
G2 | 1 | 0.68 | |
G3 | 2 | 22.57 (9.28–35.86) | |
G4 | 7 | 25.77 (19.58–31.68) | |
Type of surgery | 0.267*2 | ||
Lumpectomy | 2 | 10.51 (−3.57–24.58) | |
Mastectomy | 8 | 28.50 (11.93–34.00) | |